Besides supporting therapeutic decisions for enrolled patients by providing “fast-track” molecular results to the treating physicians, the ABP trial also aims to deepen understanding of the underlying biology and facilitate development of a framework for individualized management of ALK+ NSCLC according to molecular properties. Here, ALK is linked to non-small cell lung carcinoma.